Senegal announced today the country's first Ebola virus disease case, in a student from Guinea who was located in a Dakar hospital.
The National Institutes of Health (NIH) has partnered with an international-based consortium based in Britain to fast-forward work on an Ebola virus vaccine developed by GSK that has shown promise in nonhuman primate studies.
With an estimated price tag of $490 million, the plan's goal is to stop Ebola transmission in 6 to 9 months.
In addition, Canada pulled a lab team from Sierra Leone.
The WHO sent a team to a hot spot where one of its Ebola workers was infected.
The US Centers for Disease Control and Prevention (CDC) yesterday released guidance for handling the bodies of patients who die from Ebola infections. The advice is aimed at those performing postmortem care in US hospitals and mortuaries.
Ebola has struck the northern part of the Democratic Republic of Congo, but authorities say it is not the same strain as in West Africa.
As West Africa's Ebola toll climbed by 142 cases and 77 deaths, the WHO conceded that the size of the epidemic has been underestimated.
It's time to reassess strategies for controlling methicillin-resistant Staphylococcus aureus (MRSA) in hospitals, mainly because of poor evidence for the efficacy of screening and isolation, which have been regarded as the gold-standard approach, say three German and Swiss experts writing in The Lancet.
The WHO voiced concern about Ebola-related bans on flights to outbreak countries and other African nations.
